FDA grants final approval for Acarbose tablets ANDA: Mylan Pharma
Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has claimed that its Acarbose tablets is the generic version of Bayer’s Precose tablets, a treatment to be used with diet
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.